AbbVie (NYSE:ABBV) shares dropped around 4% on Friday even after Q3 earnings surpassed expectations at $2.95 EPS and $13.93 billion revenue against the predicted $2.87 EPS and $13.71 billion. Year-on-year, revenue fell 6%, with dips in immunology, oncology, and aesthetics by 11.3%, 8.4%, and 4.7% respectively. However, neuroscience grew by 22.1%.

Despite the revenue decline, the company cited "outstanding results" due to its non-Humira growth. CEO Richard Gonzalez announced an increased 2023 full-year guidance and quarterly dividend. The adjusted EPS guidance for 2023 is now $11.19-$11.23, up from $10.86-$11.06.